Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II clinical trial of Relaxin-2 in Heart Failure with Preserved Ejection Fraction and in Atrial Fibrillation

Next Previous
Trial Profile

A phase II clinical trial of Relaxin-2 in Heart Failure with Preserved Ejection Fraction and in Atrial Fibrillation

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relaxin (Primary)
  • Indications Atrial fibrillation; Cardiovascular disorders; Heart failure
  • Focus Therapeutic Use
  • Acronyms SOURCE-HF-01

Most Recent Events

  • 02 Apr 2026 New trial record
  • 24 Mar 2026 According to Relaxera media release, clinical trial initiation planned in H1 2026.
  • 24 Mar 2026 According to Relaxera media release, announced that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for relaxin-2 for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) as well as Atrial Fibrillation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top